BioNTech SE (BNTX) said Monday it will continue executing its strategy in 2026 to evolve into a multi-product oncology company, with the year expected to be catalyst-rich as late-stage programs advance across immunomodulators, antibody-drug conjugates, and mRNA-based cancer therapies.
The company also reported financial strength with €17.2 billion in cash and cash equivalents plus security investments, a COVID-19 vaccine revenue streams, disciplined R&D spend, and strategic partnerships that will continue to enable sustainable innovation.
